Physician profile
James C Beasley
NPI 1285019380
$12,849.07
in general payments reported to CMS, 2019-2025
24 companies · $1,665 in 2025
The $1,665 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,075 · 2022: $5,631 · 2023: $435 · 2024: $2,043 · 2025: $1,665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,142.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $8,731.64 | 2021-2023 | Lifevest |
| Novo Nordisk INC | $934.73 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $557.48 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Shield Therapeutics INC | $449.57 | 2023-2025 | Accrufer |
| Abbvie INC. | $347.05 | 2023-2025 | |
| Abbott Laboratories | $313.73 | 2024-2025 | Navitor, Freestyle Libre 3 |
| Pfizer INC. | $269.02 | 2023-2025 | |
| Lilly USA, LLC | $228.29 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $220.06 | 2023-2025 | |
| Glaxosmithkline, LLC. | $140.52 | 2024-2025 | Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.05 | 2024 | Xifaxan, Trulance |
| Daiichi Sankyo INC. | $97.42 | 2024-2025 | Injectafer |
| Phathom Pharmaceuticals, INC. | $84.30 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $72.29 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amgen INC. | $67.17 | 2023-2025 | Repatha, Otezla, Otezla |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $54.54 | 2025 | Flucelvax, Fluad |
| Impel Pharmaceuticals INC. | $47.61 | 2023 | Trudhesa |
| Aimmune Therapeutics, INC. | $28.65 | 2024-2025 | Zenpep |
| Axsome Therapeutics, INC. | $24.35 | 2024 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.68 | 2025 | Jardiance |
| Merck Sharp & Dohme LLC | $19.00 | 2024 | Capvaxive |
| Ardelyx, INC. | $14.62 | 2024 | Ibsrela |
| Kowa Pharmaceuticals America, INC. | $14.26 | 2025 | Zoryve |
| Takeda Pharmaceuticals U.S.A., INC. | $14.04 | 2025 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Beasley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.